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ABSTRACT 
 
Elevated plasmatic levels of C-type natriuretic peptide (CNP) were found in patients with chronic 
heart failure (CHF), but its use as sensitive and specific clinical bio-marker is still controversial. In 
fact, high levels of CNP were also observed in patients classified in low severity New York Heart 
Association (NYHA) classes. CNP is encoded by a gene poorly studied (NPPC, natriuretic-
precursor peptide C), where the regulatory regions are not well defined and the role of single 
nucleotide polymorphisms (SNPs) poorly ascertained. In the present work, we focused on the 
characterization of the 3’untranslated region (3’UTR) of the gene, using Rapid Amplification of 
cDNA 3’-End (3’ RACE), and we identified two novel transcript isoforms (L-3’UTR; S-3’UTR; 
accession number JF420840, HQ419060 respectively). Since it could be hypothesized that genetic 
variations could explain the observed inter-patients differences, we searched for novel SNPs, by the 
use of High Resolution Melting (HRM). Moreover, we predicted relevant microRNAs binding to 
the novel 3’UTRs that could modulate the post-transcriptional regulation of NPPC and affect the 
plasmatic levels of CNP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
The 22-aminoacids vasodilator C-type natriuretic peptide (CNP), released by the vascular 
endothelium and by the heart [Barr et al., 1996; Del Ry et al., 2011a], belongs to a family that 
includes also the urodilatin, and the ANP (atrial), BNP (brain), and DNP (dendroaspis) natriuretic 
peptides [de Bold et al., 1981; Schulz-Knappe et al., 1988; Sudoh et al., 1988; Sudoh et al., 1990; 
Schweitz et al., 1992; Del Ry et al., 2006]. In patients with chronic heart failure (CHF), plasma 
levels of ANP and BNP are elevated in relation to the clinical severity (measured according to the 
classes issued by the New York Heart Association, NYHA) and have diagnostic and prognostic 
relevance [Burnett et al., 1986; Ogawa et al., 1991; Clerico et al., 2009]. On the other hand, the 
significance of CNP is still controversial [Kalra et al., 2001]. In fact, also CNP shows elevated 
levels in CHF patients in relation to the functional and clinical severity [Kalra et al., 2003; Del Ry 
et al., 2005; Del Ry et al., 2007; Del Ry et al., 2008; Passino et al., 2008; Kalra et al., 2010; Del Ry 
et al., 2011b]. However, high levels of CNP were also observed in some patients with low NYHA 
classes, whereas others present low levels although with a severe disease, preventing its use as 
sensitive and specific clinical bio-marker [Del Ry et al., 2005].  
It could be hypothesized that genetic variations could explain the observed inter-patients 
differences. In fact, CNP is encoded by a gene poorly studied (NPPC, natriuretic-precursor peptide 
C) where the regulatory regions were not well defined and the role of single nucleotide 
polymorphisms (SNPs) was never ascertained. In a single previous work Ono et al., studied four 
SNPs within NPPC and one of them, the variant G2628A (rs5268), hypothesized to be located 
within the putative 3’UTR, was found associated with essential hypertension [Ono et al., 2002]. 
However, it should be noticed that the 3’UTR described by the authors showed a strange 
inconsistency when compared to the orthologous 3’UTRs of other mammals. The polymorphism 
rs5268 was considered to belong to the 3’UTR, simply because it was located 82 base pairs 
downstream of the stop codon. Experiments aimed to characterize the region were not performed 
and there was not any evidence that the SNP was actually located within it. Thus, in the present 
work, we focused on the characterization of the 3’UTR and we identified two novel transcript 
isoforms. Thus, we could search for novel polymorphisms and relevant microRNAs (miRNAs) that 
could modulate the post-transcriptional regulation of NPPC and affect the plasmatic levels of CNP.  
 
 
 
 
Materials and Methods 
 
Sample collection 
Human cardiac tissues.  
Patients undergone to left ventricular assist device (LVAD) implantation and at the end-stage heart 
failure (HF) (NYHA class III and IV; age: 57±11 yrs; LVEF%<20), provided biopsies necessary for 
the study. The cardiac biopsies (n=5) were collected from left ventricle (LV) at the time of the heart 
transplantation, thanks to the collaboration with the Institute of Clinical Physiology (IFC)-CNR, 
Niguarda Ca' Granda, Milan. Immediately after collection, samples were frozen in liquid nitrogen 
and stored -80°C until sample preparation. The study protocol was conform to the principles 
outlined in the Declaration of Helsinki and was approved by the local Ethics Committee of the 
Niguarda Ca’ Granda Hospital. All subjects gave written informed consent to participate in the 
study. 
Plasma samples.  
Plasma samples were collected from 63 patients (mean age 61±1 years) with a diagnosis of chronic 
heart failure (CHF) provided by Institute of Clinical Physiology, CNR-Milan. Blood samples (10 
ml), collected in ice-chilled disposable polypropylene tubes containing aprotinin, 500 KIU/ml, and 
EDTA, 1 mg/ml, were rapidly separated by centrifugation for 15 min at 4°C, and stored frozen at –
20°C in ml aliquots in polypropylene tubes until assay, performed within 1 month from sampling.  
Blood samples, used as controls, were obtained from 63 volunteers without heart disease and were 
provided by a routine biochemical analysis laboratory of the region. Plasma and blood samples 
were matched for the age of the donors. All subjects were informed and gave written consent to 
participate to the study and to allow their biological samples to be genetically analysed, according 
to the Helsinki declaration. 
Neuroblastoma cells. The human neuroblastoma SKNBE cells (kindly donated by the National 
Research Council, Genova, Italy) were grown to confluence in RPMI 1640 medium (Lonza, 
Switzerland), containing 10% heat-inactivated fetal calf serum (Sigma Aldrich Corp. St Louis, MO, 
USA), 1% glutamine (Lonza, Switzerland), 1% PEN-STREP (Lonza, Switzerland), at 37°C in a 5% 
CO2 humidified atmosphere. 
 
Nucleic acid extraction and quantification 
Total RNA was extracted by acid guanidinium thiocyanate-phenol-chloroform method from tissue 
samples obtained from human cardiac tissue with Rneasy Midi kit (Qiagen MI, Italy). Briefly, the 
tissue was homogenized with a Mixer Mill MM300 (Qiagen MI, Italy). In order to remove 
contractile proteins, connective tissue and collagen, which can interfere with the procedure, the 
protocol was modified to include proteinase K digestion. Samples were lysed in a guanidine-
isothiocynate-containing lysis buffer. After dilution of the lysate, the samples were treated with 
proteinase K. Debris was pelleted by centrifugation. Ethanol was added to the cleared lysate and 
RNA was bound to the Rneasy membrane. Contaminants were washed away, and total RNA was 
eluted in Rnase-free water. The presence of proteinase K and the tissue homogenization by Mixer 
Mill MM300 allowed us a high yield in RNA extraction. For the extraction of total RNA from the 
human neuroblastoma cell line, cells were washed twice with DPBS-A, treated with trypsin-EDTA 
(Invitrogen MI, Italy), and counted in a haemocytometer. Three millions cells were pelleted by 
centrifugation at 200 g, then the QIAgen Rneasy Mini Kit (Qiagen MI, Italy) was used according to 
the manufacturer's protocol for all large scale samples. RNA concentration was determined 
spectrophotometrically (Beckman DU 640) at 260 nm. The ratio of readings at 260 nm and 280 nm 
(A260/A280) provided an estimate of the purity of RNA with respect to contaminants that absorb in 
the UV spectrum, such as proteins and DNA. The integrity and purity of total RNA was also 
detected by electrophoresis of samples on ethidium bromide agarose gels. Only samples that 
showed clear and distinct 28S and 18S ribosomal RNA bands and had spectrophotometric OD 
260/280 ratios of 1.9-2.1 were used. A known amount of total RNA (Ambion Inc. Austin, USA) 
was used as marker. DNA was extracted using the commercially available kit QIAmp DNA Mini 
and Blood Mini kit (Qiagen MI, Italy). Quantification of all experimental DNA samples was 
assessed using Qubit® Fluorometer (Invitrogen, MI, Italy). Briefly, total gDNA was extracted using 
the recommended protocol. Proteinase K (20 μl) was added to the sample and the mixture was 
further incubated at 56°C for 1 h. Lysis buffer (200 μl) was added to the sample, mixed thoroughly 
by vortexing, and incubated at 56°C for 10 min. Ethanol (95–100%, 200 μl) was then added to the 
sample, mixed thoroughly by vortexing, and the whole mixture was applied to a QiAmp spin 
column with a collection tube. The mixture was allowed to bind to the column by centrifugation at 
6000 g for 1 min. The QiAmp spin column was washed with buffers followed by centrifugation at 
6000 g for 1 min to remove excess ethanol. The spin column-bound gDNA was eluted with the 
elution buffer (50 μl) and was incubated at room temperature for 5 min, and then was centrifugated 
at 6000 g for 1 min. DNA was incubated at 65°C for 1 hour. 
 
DNA sequences alignment and miRNA target prediction 
The alignment between the available human consensus sequence (RefSeq) and its orthologous of 
mouse, rat, cow, pig, goat, and guinea pig was performed with UCSC Genome Browser (URL: 
http://genome.ucsc.edu/). The sequences obtained from our experiments were aligned against the 
human genome as well as against mammals’ genomes using Nucleotide BLAST (URL: 
http://blast.ncbi.nlm.nih.gov/Blast.cgi). Putative miRNA-binding sites within the 3’UTRs of NPPC 
were identified by means of miRanda (http://www.microrna.org). This algorithm evaluates the 
sequence complementarity between the mature miRNA and the target site, locates the binding 
position on the target, and calculates the binding free energy (expressed as ΔG, Gibbs free energy, 
in kcal/mol). The miRanda software was ran locally, with a threshold of ΔG≤-15.00 kcal/mol, using 
the two identified isoforms as target sequences and the most updated list of human mature miRNAs 
as query. MiRNAs were downloaded from miRBase a public database, available at the URL: 
http://www.mirbase.org/.  
Rapid Amplification of cDNA 3’-End (3’-RACE) 
Total RNA was reverse-transcribed with the commercially available kit Cloned AMV reverse 
transcriptase (Cloned AMV First-Strand cDNA Synthesis Kit, Invitrogen, MI, Italy), following the 
protocol suggested by the produced. For the identification of the 3’end, a rapid amplification of 
cDNA ends (3’-RACE) was performed. Briefly, the cDNA was synthesized from 4 μg of total RNA 
extracted from human cardiac tissue and 5 μg of RNA extracted from human neuroblastoma cells, 
using an universal primer (RACE-1) containing an anchor sequence, in a 20 μl reaction. Reaction 
protocol started with 42°C for 1 h 30 min and followed by 85°C for 5 min. cDNA was precipitated 
with glycogen, sodium acetate 3M, pH 5.2, and absolute ethanol. cDNA was then amplified using a 
gradient PCR as follows: an initial denaturation step (8 min at 95°C) followed by 35 amplification 
cycles (30 sec at 95°C, 30 sec at 53°C-60°C, 1 min and 30 sec at 72°C). The sequences of the 
primers used are reported in table 1, where the forward primer (RT-F) was gene-specific, whereas 
the reverse primer (RACE-2) contained a sequence complementary to the anchor sequence of the 
RACE-1 primer. Both were used for the first amplification, followed by a second nested PCR 
reaction with the gene-specific forward primer (RT-F’) and the universal reverse primer (RACE-3), 
complementary to the anchor sequence of RACE-2, using the same amplification protocol as 
before. PCRs were performed in a volume of 25 μL per reaction. Reaction mixture included 2 μL of 
template cDNA, 2 μL of each primer (Bio-Fab Research RO, Italy), 3 μL of MgCl2, 2.5 μL of 
Buffer, 0.25 μL of dNTP, 0.25 μL of Taq polimerase and sterile H2O. The PCR products were 
separated on a 2% agarose gel. Bands were excised and purified with a QIAquick gel extraction kit 
(Qiagen MI, Italy) and sequenced with the standard Sanger reaction on an Applied Biosystem ABI 
PRISM 3730 XL automated sequencer.  
PCR assay  
To identify SNPs within the two identified 3’UTRs, specific primer couples SF/SR and LF/LR were 
designed within them, to allow PCR amplification of 386- or 846- base pairs long fragments, 
respectively. Samples were amplified with a touch-down protocol. Touch-down amplification was 
performed with an initial step of 95°C for 8 min, followed by 20 cycles of 95°C for 30 sec, 
annealing temperatures starting at 68°C for 30 sec (decreasing by 1 C/cycle), and 72°C for 1 min 
and 15 sec for extension. This step was followed by 30 cycles of 95° C for 30 sec, 51°C for 30 sec, 
72° C for 1 min and 15 sec, and a final extension at 72° C for 8 min. PCRs were performed in a 
volume of 20 μL per reaction. Reaction mixture included 1 μL of template DNA, 0.1 μL of each 
primer (Bio-Fab Research RO, Italy), 2.4 μL of MgCl2 (Solis BioDyne Tartu, Estonia), 2 μL of 
Buffer (Solis BioDyne Tartu, Estonia), 4 μL of Solution S (Solis BioDyne Tartu, Estonia), 0.2 μL of 
dNTP (Solis BioDyne Tartu, Estonia), 0.3 μL of Taq polymerase (Solis BioDyne Tartu, Estonia), 
and sterile H2O. The PCR products were separated on a 2% agarose gel. Bands of the expected sizes 
were purified with Microcon Centrifual Filter Device (Millipore) and sequenced. 
High Resolution Melting (HRM) 
To analyze exon 2 of NPPC gene, DNA extracted from plasma and blood samples was amplified 
using HRM-F and HRM-R primers reported in table 1, producing an amplicon of 162 bp. The PCR 
for HRM was carried out with the Type-it® HRM PCR kit (Qiagen MI, Italy) using the 
LightCycler® 480 (Roche) with the following conditions: 95°C for 5 min followed by 50 cycles of 
95°C for 10 sec, 62°C for 30 sec and 72°C for 10 sec. Afterwards, amplicons were heated from 
65°C to 95°C for 1 sec and cooled to 40 °C for 1 sec. Finally, the melting curves were generated by 
measuring the fluorescence emitted by the fluorochrome EvaGreen® during the increase of the 
temperature, from 65°C to 95°C, with an increment speed of 0.02°C/sec. Results were analyzed 
using LightCycler® 480 Gene Scanning software to detect sequence variations in PCR amplicons.  
 
Results 
When the human NPPC gene (RefSeq: NM_024409.2) was aligned together with the mammal 
orthologous (as listed in UCSC genome browser), its 3’UTR differed significantly. In fact, mouse, 
rat, and cow showed a splice junction, joining the portion of 20 nucleotides downstream of the stop 
codon with a genomic region distant 2845 nucleotides, whereas the human 3’UTR was reported as a 
simple short sequence of 40 nucleotides downstream of the stop codon. This corresponded, 
essentially, to the clones BC105065 and BC105067, as described by Strausberg et al. [Strausberg et 
al., 2002].  
However, GenBank (URL: http://www.ncbi.nlm.nih.gov/gquery/?term=genbank) revealed also the 
presence of spliced ESTs for the human gene (Genbank ID DR003533). Thus, we defined more 
precisely the 3’UTR with the use of the 3’-RACE. The neuroblastoma cell line expressed a 3’UTR 
where 20 nucleotides downstream of the stop codon were joined (by splicing) with a region 1387 
nucleotides far away. The figure 1 depicts the electropherogram showing the splice junction of this 
new isoform, never described before, where the 3’UTR is 356 nucleotides-length that we 
denominated “short” (S). When the human cardiac tissue was analysed, we found an alternative 
3’UTR, where a splice junction joined a portion of 20 nucleotides downstream of the stop codon 
with a region 3089 nucleotides far away. The figure 2 shows the splice junction and depicts that this 
new isoform (with the 3’UTR of 480 nucleotides-long) resembles closely the conserved mammal 
orthologous. This isoform matches closely also with some previously described spliced ESTs and it 
was denominated as “long” (L). The S- and L- isoforms were submitted to GenBank. The former is 
annotated as “Homo sapiens natriuretic peptide precursor type C mRNA, partial cds and 3'UTR, 
318 bp”, with the accession number HQ419060, whereas the latter as “Homo sapiens natriuretic 
peptide precursor type C mRNA, partial cds, 427 bp” with the accession number JF420840. The 
figure 3 shows the UCSC Genome Browser window with the novel isoforms, the non-human genes, 
the spliced ESTs and the novel and corrected RefSeq. GenBank automatically assigned the protein 
sequences IDs ADQ54381.1 and ADZ36320.1 for the S- and L-, respectively. It should be noticed 
that the coding sequence does not differ to the previously established RefSeq (NM_024409.2). We 
confirmed the presence of the S- and L- isoforms with specific PCRs, revealing that, actually, both 
the isoforms are expressed in the cardiac tissue, with the L- apparently more expressed than the S-
one, according to the band intensities obtained on the electrophoresis gel.  
It should be also noticed that the polymorphism rs5268 did not fall within the transcribed mRNA, 
since it is located within the intronic sequence. However, we cannot exclude that it was associated 
with hypertension because of effects on the regulation of the splicing, or of the linkage 
disequilibrium (LD) with other SNPs nearby. Unfortunately, only two SNPs (rs3107179 and 
rs5262, the former located approximately 910 base pairs at the 5’ region of the gene and the latter 
1820 bp downstream of the stop codon), were genotyped in the contest of the HapMap project 
(URL: http://hapmap.ncbi.nlm.nih.gov/), thus preventing to define a precise LD map of the region. 
Moreover, using the available online databases dbSNP (URL: 
http://www.ncbi.nlm.nih.gov/projects/SNP/) and GenBank we could not predict whether the rs5268 
was linked with other relevant SNPs in the gene region. In particular, we observed a poor 
characterization of the SNPs within the locus. Thus, we attempted to identify novel SNPs, in 
particular within the novel 3’UTRs. To identify any polymorphism, we used gene-specific primers 
for the S- and L- isoforms and the PCR products (386 bp and 846 bp, respectively) from eight 
independent chromosomes were sequenced. Although, the number of chromosomes was limited, we 
did not find any novel polymorphism and this finding agrees with the lack of genetic variations 
within dbSNP. Thus, we can conclude that among Caucasians, both the S- and L- isoforms are 
devoid of common polymorphisms, whereas we cannot exclude the presence of rare variants. SNPs 
were not found either in controls or in patients. Following the limited information from HapMap 
project, it seemed that the two SNPs encompassing the locus were in LD each other (D’=0.979; 
r2=0.34). Thus, we hypothesized that most of the SNPs in the gene region could be located within 
one LD-island. Then, we focused our attention to the central portion of the gene (i.e. the second 
exon), that putatively could bear SNPs in LD with the rs5268. In particular, the second exon 
encodes for the critical portion of the protein, and nine single nucleotide variations were described 
in dbSNP. Unfortunately, these variations were not validated experimentally and their allele 
frequencies were not available. It is predicted that rs5266, rs76093905, and rs138975043 do not 
encode for aminoacid substitutions, whereas the others (rs5267, rs79480591, rs13305994, 
rs80265630, rs13305993, rs80022541) do. No SNPs were described within the exon 1 in dbSNP. 
We focused on SNPs rs5267, rs79480591, rs13305994, and rs80265630, very close each others and 
we have undertaken a mutation screening in order to characterize whether these SNPs could have a 
meaningful frequency among Caucasians. We screened 126 independent chromosomes from CHF 
patients and 126 from healthy controls, with the use of HRM. A total of six samples showed HRM 
peaks slightly shifted as compared to the other samples and the related amplicons were sequenced. 
The results showed a complete lack of genetic variations among our series of samples.  
After having excluded any novel polymorphisms within the 3’UTRs and within the second exon of 
the gene, we wondered whether the novel 3’UTRs could bear miRNA binding sites, important for 
the post-transcriptional regulation of NPPC. Thus, we predicted the putative miRNAs targeting the 
S- and L- 3’UTRs and we found 750 and 1024 miRNAs, respectively (see supplementary tables 1 
and 2). When considering only those showing at least 10 contiguous bases perfectly matching the 
target, 41 miRNAs were predicted to bind the L- and 11 the S-form. When the human forms were 
aligned together with its mammal orthologous (rhesus, mouse, dog, and cow), the S- 3’UTR did not 
show any conserved sequence, whereas we found that L-form encompassing between 
chr2:232786879 to chr2:232786909 (fig. 3) was highly conserved showing >97% of homology. The 
miRNAs predicted to bind the conserved sequence are reported in table 2.  
 
Discussion 
 
The main findings of the present study are the identification of two novel isoforms of the 3’UTRs of 
the gene NPPC: the S-isoform (318 bp), firstly identified in a human neuroblastoma cell line, and 
the L-isoform (427 bp), identified in the human heart tissue from CHF patients. It should be noticed 
that the S-3’UTR was never observed among spliced human ESTs, nor among the orthologous 
counterpart, and that this isoform shows low conservation among mammals. Since it was detected 
in a cancer cell line and, at low level, in heart tissues from patients undergone to LVAD implants, it 
could be speculated that the S-form is the result of a sort of “aberrant” splicing, consequence of 
cellular stress or disfunction. Alternatively, it cannot be excluded that the S-form has important 
regulatory functions peculiar of the human normal physiology of cardiomyocytes and neurons. In 
any case, further studies are warranted in order to better understand the meaning of this quite 
unconventional spliced mRNA. The L-3’UTR has a structure very similar to other mammalian 
species and we could observe that the rs5268, previously attributed to the 3’UTR of the gene, 
actually falls within the intervening intronic sequence. We did not identify any (novel) SNP within 
the L- or the S- 3’UTRs, as well as within the second exon of the gene, perhaps because the 
existence of an important selective pressure on these regions. Since the work from Ono et al. [Ono 
et al., 2002], was carried out in Japanese, it cannot be excluded that the association with the 
hypertension is due to polymorphisms private of the Asiatic population, in LD with rs5268. 
However, this explanation is quite unlikely. In fact, differences between Caucasians and Asians are 
quite limited and, according to dbSNP, there is a lack of genetic variants in the considered regions 
also among Asians. If the hypertension were really associated with the rs5268, the mechanism could 
be linked to a deregulated splicing of the last novel intron, or to a LD with other SNPs located at the 
5’ end of the gene. We suggest also that the inter-patients differences in plasmatic CNP levels are 
not due to SNPs within the 3’UTR or the coding sequence of the NPPC gene. The role of SNPs at 
the 5’ end of the gene needs further investigations. 
In order to better characterize the novel 3’UTRs, we pointed our attention on possible target sites 
for miRNAs. There is increasing evidence that miRNAs have distinct expression profiles and play 
crucial roles in various physiological and pathological processes. In this regard, it could be 
interesting to analyze the role of miRNAs in the post-transcriptional regulation of NPPC. Currently, 
information about the possible role of miRNA regulation in relation to CNP is not available. We 
found, following a literature search, only two studies on cardiomyocyte-specific miRNAs (miR-
133a and miR-208) and the levels of ANP and BNP. Liu et al. showed that the levels of miR-133a 
are associated with the activity of ANP and BNP, in cardiovascular disease [Liu et al., 2011], 
whereas van Rooij et al. discovered that the BNP is up-regulated in the heart of miR-208 knockout 
mice [van Rooij et al., 2007]. Following our search with appropriate algorithms, we found that both 
the S- and L-forms are predicted to be target for a large number of miRNAs. Among them, we 
found the cardiomyocyte-specific miRNAs miR-133a and miR-208 (binding the L-form) [Babiarz 
et al., 2012]. Moreover, we detected also several miRNAs actively involved in growth, 
development, function, failure, and stress response of the heart [Ikeda and Pu, 2010; van Rooij, 
2011], such as miR-21 [Thum et al., 2008], miR-24 [Sun et al., 2004], miR-33b [Najafi-Shoushtari 
et al., 2010], miR-125b [van Rooij et al., 2006], miR-133b [Sun et al., 2004], miR-143 [Esau et al., 
2004; Boettger et al., 2009], miR-145 [Boettger et al., 2009], miR-150 [Zhou et al., 2007], miR-195 
[Sun et al., 2004; van Rooij et al., 2006], miR-212 [Ucar et al., 2010], miR-296 [Sun et al., 2004]. 
Interestingly, the deletion of miR-133a1 and miR-133a2 caused lethal ventricular-septal defects, 
dilated cardiomyopathy, and heart failure in double-mutant mice [Liu et al., 2008]. Moreover, miR-
208a is encoded by an intron of the alphaMHC gene, encoding for a major cardiac contractile 
protein involved in cardiomyocyte hypertrophy [van Rooij et al., 2007]. MiR-208a is also co-
expressed with the MYH6 gene whitin the adult heart, regulating the expression of two slow 
myosins [van Rooij et al., 2009]. On the other hand, miR-21 regulates the ERK-MAP kinase 
signaling pathway in cardiac fibroblasts, which affects global cardiac structure and function [Thum 
et al., 2008]. Finally,  miR-125b, miR-24, miR-195 were found up-regulated in 2 independent 
mouse models of cardiac hypertrophy and specific analyses showed an increased expression of 
these miRNAs in idiopathic end-stage failing human hearts  [van Rooij et al., 2006]. 
It should be stressed that the most conserved sequence within the L-form is predicted to bind to the 
miRNAs listed in table 2. Interestingly, these miRNAs show a high degree of complementarity to 
the target (at least 10 contiguous base pairs are perfectly matching the target), with a threshold of 
ΔG ≤-15.00 kcal/mol. Thus, it could be hypothesized that a large number of them is crucial for the 
binding to the gene sequence. At the present time, information about most of the listed miRNAs is 
not available, in fact many of them have been recently identified. However, among them, we 
noticed the presence of let-7, one of the best characterized miRNAs, firstly identified in C. elegans 
as a regulator of development and cellular proliferation [Lagos-Quintana et al., 2001; Lee and 
Dutta, 2007]. In a future, the knowledge of the role played by the genetic background in the 
regulation of CNP, as well as of other markers, could be of extreme importance also for the clinical 
practice. In fact, in order to better distinguish between the physiological and the pathological levels 
of specific bio-markers, personalized thresholds will be defined with the help of the genetic 
information. More studies are warranted in order to better understand the genetic bases explaining 
the regulation of NPPC. 
 
 
 
 
 
 
Figure 1: A) Electropherogram showing the splice junction of 3’UTR “short”; B) FASTA 
sequence 356 nucleotides long. In bold the stop codon, underlined the splice junction. 
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NNGNNGNGGGCCATCTCAGGGCGACCGGTCGCGACTGCTCCGGGACCTGCGCGTGGACACCAAGTCGCGGGCAGC
GTGGGCTCGCCTTCTGCAAGAGCACCCCAACGCGCGCAAATACAAAGGAGCCAACAAGAAGGGCTTGTCCAAGGG
CTGCTTCGGCCTCAAGCTGGACCGAATCGGCTCCATGAGCGGCCTGGGATGTTAGTGCGGCGCCCCCTGGCGGCG
GGAGAAGAATGATTCTGACACTTGGGGACCAGCCTTCAGTAGCTACCCTTGGAATGCCTTTGCTCTCTTCTCTCC
TGTCTAAACAACAAAGAGACGGAGTCTGAGGCCTCGAAAAAAAAAAAAAAAAAACC 
Figure 2: A) Electropherogram showing the splice junction of 3’UTR “long”; B) FASTA 
sequence 480 nucleotides long. In bold the stop codon, underlined the splice junction. 
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NNNNNNNNGNGGCGCATCTCAGGGCGACCGGTCGCGACTGCTCCGGGACCTGCGCGTGGACACCAAGTCGCGGGCAGCGT
GGGCTCGCCTTCTGCAAGAGCACCCCAACGCGCGCAAATACAAAGGAGCCAACAAGAAGGGCTTGTCCAAGGGCTGCTTC
GGCCTCAAGCTGGACCGAATCGGCTCCATGAGCGGCCTGGGATGTTAGTGCGGCGCCCCCTGGCGGCGGATCGGGAACTG
GCTCCGTTGTGCTGAGGTCATCTTTGGTCATCAGCCTCCAGCATCTGGAAACACCTCCAACGCAATGTGGCTTTTACATT
TCTTTCTTTCTTTCTTTTTTTTTCCTGGTACTGGGAATACACAACACCAGCTGTTTTATTATTATTTGGGGAGGGGGTTG
TGATTTTATTATTTGTTTTTTTAAAATGAAAAATAAAAAGTTATATATTAAAAAAAAAAAAAAAAAAAACCCGCCCTTTA
AAAACAACAAAN 
Figure 3: A) NPPC gene structure from Genome Browser. B) The conservation score for the 
L-3’UTR. C) The sequence of the most conserved region within the L-3’UTR from 
chr2:232786879 to chr2:232786909. 
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Table 1: primer sequences for PCR reactions.  
 
Primer Id Sequence 
RACE-1  5'-CTCGCGAGCGCGTTTAAACGCGCACGCGTTTTTTTTTTTTTTTTTTVN-3’ 
RACE-2 5’-GCTCGCGAGCGCGTTTAAAC-3' 
RACE-3 5’-GCGTTTAAACGCGCACGCGT- 3’ 
RT-LF  5’-CGCCGCCGAAGGTCCCG-3' 
RT-LF'  5’-GTCAGAAGAAGGGCGACAAG-3’ 
SR 5’-ACTTGGGACGAAACTTACAC-3’ 
LF 5’-CCGAACAGACTCGTGGAAAT-3’ 
LR 5’-CCAGGTACGAACCAATGGAG-3’ 
HRM-F 5’-TGTTGGCTCCTTTGTATTTGC-3’ 
HRM-R 5’-GTCAGAAGAAGGGCGACAAG-3’ 
 
 
 
 
 
 
 
 
 
 
Table 2: List of predicted miRNAs targeting the highly conserved sequence within L-3’UTR depicted in figure 3 and their corresponding 
ΔG binding free energy. 
 
 
1 Position of the miRNA-target duplex. Numbering is related to the L- 3’UTR, where position 1 is the chromosomal position chr2: 232787025 and position 232790137 is the stop 
codon. 
2 Maximal number of contiguous bases perfectly matching the target (the bold characters correspond to the starting/stop sites of the perfect pairing) 
 
 
 1st binding 
site 
  2nd binding 
site 
  3rd binding 
site 
    
  pairing 1   pairing 1   pairing 1    
miRNA ID ΔG 
(kcal/mol) 
from to ΔG 
(kcal/mol) 
from to ΔG 
(kcal/mol) 
from to Perfect pairing 2 Total binding free                             
energy (kcal/mol) 
hsa-let-7a-2-3p -20.08 159 175 -17.01 4 28    11 -37.09 
hsa-let-7e-3p -19.20 159 176       10 -19.20 
hsa-miR-26b-5p -15.18 140 162       10 -15.18 
hsa-miR-103b -16.94 149 175 -18.16 11 39    10 -35.10 
hsa-miR-1236 -21.00 142 169       10 -21.00 
hsa-miR-130b-5p -16.12 151 170       11 -16.12 
hsa-miR-488-5p -17.53 2 29 -15.78 140 162    11 -33.31 
hsa-miR-2114-5p -21.76 152 172       11 -21.76 
hsa-miR-2355-5p -17.18 143 164 -18.99 10 33    10 -36.17 
hsa-miR-4465 -16.42 138 162 -16.01 107 127 -18.80 29 60 10 -51.23 
hsa-miR-4659b-3p -16.45 140 168       10 -16.45 
hsa-miR-4685-3p -18.31 150 169       10 -18.31 
hsa-miR-5006-3p -18.59 142 169       10 -18.59 
hsa-miR-642b-5p -26.79 149 171       16 -26.79 
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